Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;98(3):e13303.
doi: 10.1111/sji.13303. Epub 2023 Jun 20.

Incidence and predictors of infections in patients with advanced non-small cell lung cancer treated with checkpoint inhibitor immunotherapies: A monocentric retrospective cohort study

Davide Fiore Bavaro  1 , Lucia Diella  1 , Pamela Pizzutilo  2 , Annamaria Catino  2 , Fabio Signorile  1 , Francesco Pesola  2 , Alessandra Belati  1 , Ilaria Marech  2 , Vito Garrisi  3 , Nino Lamorgese  2 , Francesco Di Gennaro  1 , Annalisa Saracino  1 , Domenico Galetta  2
Affiliations
Free article

Incidence and predictors of infections in patients with advanced non-small cell lung cancer treated with checkpoint inhibitor immunotherapies: A monocentric retrospective cohort study

Davide Fiore Bavaro et al. Scand J Immunol. 2023 Sep.
Free article

Abstract

Immune checkpoint inhibitors (ICIs) represent the cornerstone of the current treatment of non-small cell lung cancer (NSCLC). However, the occurrence of concomitant infections might hamper success. All consecutive patients with advanced NSCLC who started ICIs as a first- or second-line therapy from January 1, 2017 to June 30, 2020 were retrospectively evaluated. The occurrence of infectious events during ICIs was correlated with clinical characteristics, including previous Cytotoxic Chemotherapy (CC), occurrence of immune-related-adverse-events (irAEs). A total of 211 patients were included, 46 (22%) females, with a median (q1-q3) age of 69 (62-76) years. Overall, 85 patients (40%) received ICIs as a first treatment line and 126 (60%) as a second line; 40 patients (19%) had at least one infection during ICIs, and 17 (8%) more than one. Notably, autoimmune diseases (P < .005), neutropenia (P = .001) or infections during previous CC (P = .001), irAEs (P = .006), or steroid therapy for irAEs (P < .001) were associated with infection development. By multivariate Cox-regression, autoimmune diseases (aHR = 6.27; 95%CI = 2.38-16.48; P < .001) and steroid therapy for irAEs (aHR = 2.65; 95%CI = 1.27-5.52; P < .009) were associated with a higher risk of infection during ICIs. Interestingly, autoimmune diseases were confirmed as risk factors in patients treated with ICIs as a first line, while previous infections were the only independent predictor of infections in patients treated with ICIs as a second line. Patients with NSCLC treated with ICIs with concurrent autoimmune disease, receiving steroid therapy for management of irAEs, or having a history of previous infections during CC should be actively monitored for the risk of developing infectious complications.

Keywords: immune‐checkpoint inhibitors; immunocompromised host; infection in cancer; non‐small‐cell lung cancer; opportunistic infections.

PubMed Disclaimer

References

REFERENCES

    1. Reck M, Rodríguez‐Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐cell lung cancer. N Engl J Med. 2016;375(19):1823‐1833. doi:10.1056/NEJMoa1606774
    1. Michot JM, Bigenwald C, Champiat S, et al. Immune‐related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139‐148. doi:10.1016/j.ejca.2015.11.016
    1. Kanjanapan Y, Yip D. Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy. Cancer Med. 2020;9(23):9027‐9035. doi:10.1002/cam4.3532
    1. Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19. doi:10.1186/2051-1426-2-19
    1. Del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman‐Sidi G. The Spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63(11):1490‐1493. doi:10.1093/cid/ciw539

LinkOut - more resources